Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Autor:	Arpín EC; Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain., Sobrino TG; Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain., Vivero CD; Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain., del Campo Amigo Jorrín M; Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Regal AR; Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain., González JP; Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain., Bouzas ML; Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.
Jazyk:	angličtina
Zdroj:	Neurodegenerative disease management [Neurodegener Dis Manag] 2016; Vol. 6 (1), pp. 5-12.
DOI:	10.2217/nmt.15.53
Abstrakt:	Aim: To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy. Patients and Methods: We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years. Results: In the study population (n = 29), baseline mean CCI was 0.37 ± 0.04 and final CCI 0.36 ± 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters. Conclusion: Natalizumab may have a neuroprotective effect.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu